Document is current
Any future updates will be listed below
-
Authors
Defer, Gilles
Fedrizzi, Sophie
Chevanne, Damien
Montastruc, François
Briant, Anais R.
Parienti, Jean-Jacques
Peyro-Saint-Paul, Laure https://orcid.org/0000-0003-0301-1058
,
Defer, G.
Derache, N.
Branger, P.
Casez, O.
Vaillant, M.
Labauge, P.
Magy, L.
Montcuquet, A.
Castelnovo, G.
Cohen, M.
Bourre, B.
Kwiatkowski, A.
De Broucker, T.
Creange, A.
Heinzlef, O.
Wiertlewski, S.
Gueguen, A.
Romero, J.
Devos, P.
Planque, E.
Schaeffer, S.
Collongues, N.
De Seze, J.
Senant, J.
Bonnan, M.
Ciocanu, D.
Pittion, S.
Douay, X.
Zephir, H.
Peaureaux, D.
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03029897 at ClinicalTrials.govDocuments that mention this clinical trial
Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial
https://doi.org/10.1007/s40264-020-01009-z
-
Funding
Funding for this research was provided by:
Agence Réionale de Santé Normandie
RBN-SEP Association
- License Information
-
More Information
Article History
Accepted: 27 September 2020
First Online: 13 October 2020
Declarations
:
: This study was supported by the Regional Health Agency of Normandy (ARS Normandie) and the RBN-SEP Association, a multiple sclerosis association.
: Gilles Defer received personal compensation for the scientific advisory board from Biogen, Novartis, Genzyme, and Teva Pharmaceutical Industries Ltd and has received funding for travel and/or speaker honoraria from Merck Serono, Biogen, Novartis, Genzyme, and Teva. His institution received grants supporting research in his department from Merck Serono, Biogen, Novartis, and Genzyme. Sophie Fedrizzi, François Montastruc, Damien Chevanne, Anais R. Braint, and Laure Peyro-Saint-Paul have no conflicts of interest that are directly relevant to the content of this article. Jean-Jacques Parienti received personal compensation from MSD, Viiv, and Gilead.
: The study protocol was approved by the Ethics Committee of Nord-Ouest III (France) with approval number 2016–42.
: All participants provided a written informed consent.
: Not applicable.
: Anonymized data can be made available to investigators upon request to the corresponding author.
: Not applicable.
: All authors read and approved the final version. Gilles Defer designed and conceptualized the study, participated as a neurologist for one of the centers of the trial, analyzed the data, and drafted the manuscript for intellectual content. Sophie Fedrizzi interpreted the data and revised the manuscript for intellectual content. Damien Chevanne had a major role in the acquisition of data and revised the manuscript for intellectual content. François Montastruc designed and conceptualized the study and revised the manuscript for intellectual content. Anais R. Briant performed the statistical analysis and revised the manuscript for intellectual content. Jean-Jacques Parienti designed and conceptualized the study, performed the statistical analysis, and revised the manuscript for intellectual content. Laure Peyro-Saint-Paul designed and conceptualized the study, analyzed the data, and drafted the manuscript for intellectual content.
